In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...

"Not all GLP-1s are the same." Retatrutide, the 'King Kong' drug to mimic bariatric surgery Eli Lilly isn't pivoting away from weekly weight loss injections entirely. It's also working on another ...

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

Patrik Jonsson is an executive vice president at Eli Lilly ... injection. If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss ...

Patrik Jonsson is an executive vice president at Eli Lilly and president of Lilly Cardiometabolic Health.Courtesy Eli Lilly; Getty Images; BI Illustration Eli Lilly makes the popular shots Mounjaro ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Most major weight-loss drugs are delivered by weekly injections, including Eli Lilly’s popular Zepbound ... How they work, what they cost, side effects, and everything to know The growing ...

Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection ... lead from rival Eli Lilly (LLY.N), opens new tab in the competitive obesity drug market.

Each of these GLP-1 treatments are developed by either Novo Nordisk or Eli Lilly. Where to invest ... what could happen with approved weight loss drugs when you consider competitors and Holz's ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli Lilly ...